Zomedica Corp (NYSE American:ZOM)
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +296.43% increase from the last price of 0.30.
Similarly, Is ZOM a good stock to buy?
ZOM stock could provide some good gains in the long term if its veterinary diagnostic and therapeutic technologies can gain sufficient market traction. However, the stock remains a speculative investment that owed its previous tops to the Reddit meme that lifted other stocks like GameStop and AMC.
Will ZOM stock recover? ZOM stock will likely struggle to recover in price over the next few months. It’s going to be awhile before this early stage company will again have the chance to prove itself to investors.
Thereof, How much will ZOM be worth?
The above Stellar coin forecast reveals powerful information about the long term Stellar lumens growth and potential. Prices range from as low as $0.25 to as high as $13 per XLM coin, proving the asset has long term value.
…
Conclusion.
| Year | Potential High | Potential Low |
|---|---|---|
| 2024 – 2025 | $7.75 | $1.75 |
Will ZOM go up tomorrow?
Tomorrow’s movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish . This stock started moving upwards as soon as it opened.
…
Munafa value: 55 as on 08 Fri Apr 2022.
| Upside target | 0.33 |
|---|---|
| Downside target | 0.29 |
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by « changes at our current distributor that we believe have impacted its ability to market our products effectively. » Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Is ZOM stock buy or sell?
HC Wainwright is very positive about ZOM and gave it a « Buy » rating on Nov 16, 2020.
Is Acasti Pharma a good stock to buy?
Is ACASTI PHARMA Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: ACST) stock is to Buy ACST stock.
Is Zomedica undervalued?
InvestorPlace’s Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.
Will Acasti Pharma go up?
Acasti Pharma Inc (NASDAQ:ACST)
The 1 analysts offering 12-month price forecasts for Acasti Pharma Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +327.35% increase from the last price of 1.17.
Why is Acasti Pharma dropping?
Acasti Pharma stock dropped from $2.18 to under $1 in a single trading session. Valentine’s Day turned out to be no sweeter for ACST stock. The stock fell further when the company posted a larger loss than expected. For the company’s 2020 fiscal third quarter, it posted a loss of 14 cents per share.
Is AQST a good stock to buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: AQST) stock is to Strong Buy AQST stock.
Is ZOM a long-term hold?
ZOM Stock Is a High-Risk Trade, Not a Long-Term Investment | InvestorPlace.
Is ZOM a meme stock?
A couple of meme stocks that stand out as incredibly risky today are Zomedica ( ZOM 1.80% ) and Digital World Acquisition Corp ( DWAC 0.73% ).
What does Zomedica Corp do?
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians.
Is ZSAN a buy?
Out of 1 analyst, 0 (0%) are recommending ZSAN as a Strong Buy, 0 (0%) are recommending ZSAN as a Buy, 1 (100%) are recommending ZSAN as a Hold, 0 (0%) are recommending ZSAN as a Sell, and 0 (0%) are recommending ZSAN as a Strong Sell. What is ZSAN’s Earnings Per Share (EPS) forecast for 2022-2022?
Is ACST undervalued?
Valuation metrics show that Acasti Pharma, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of ACST, demonstrate its potential to underperform the market.
Will ACST reverse split?
Acasti Pharma, Inc. (ACST) will effect a one-for-eight (1-8) reverse split of its common stock. The reverse stock split will become effective on Tuesday, August 31, 2021. In conjunction with the reverse split, the CUSIP number will change to 00430K873.
Will AQST get FDA approval?
AQUESTIVE THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AQST-109 FOR EMERGENCY TREATMENT OF ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS. AQUESTIVE THERAPEUTICS INC – EXPECTS TO REPORT TOPLINE RESULTS FOR FULL EPIPHAST STUDY IN FIRST HALF OF 2022.
What is Truforma?
Truforma is a blood testing kit for veterinarians. It’s based on bulk acoustic wave (BAW) sensors from Qorvo (NASDAQ:QRVO). The waves are run through pet blood samples to test for adrenal and thyroid diseases.
Where is Zomedica located?
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company offering diagnostic and therapeutic products for companion animals by focusing on the unmet needs of clinical veterinarians.
What is ZOM product?
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health.
How many employees does Zomedica have?
Zomedica Pharmaceuticals Inc. has 27 total employees across all of its locations and generates $4.13 million in sales (USD). There are 2 companies in the Zomedica Pharmaceuticals Inc.
…
| Year | Operating Income |
|---|---|
| 2017 | -8.08 |
| 2018 | -16.58 |
| 2019 | -19.78 |
| 2020 | -16.76 |
Will Qtrypta be approved?
Zosano filed for approval of Qtrypta in December 2019 and disclosed news of the FDA’s acceptance of the submission for review the following March, resulting in a PDUFA date in October 2020. A late 2021 resubmission could see Qtrypta win FDA approval up to two years later than originally planned.
What is NAKD stock?
Cenntro Electric Group Ltd (NAKD)
Join TheMoney.co community and don’t forget to share this post !
